A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.

Authors
Publication date
1 August 2004
Publisher
'FASEB'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Supporting member

      Lancaster E-Prints

      redirect
      oaioai:eprints.lancs.ac.uk:8843
      Last time updated on 08/03/2012